First test focused on risk assessment of Acute Kidney Injury in pediatric patients.
An expansion of BioPorto Diagnostics Metabolic Marker Portfolio
These Terms and Conditions (“Terms") governing the sale of products and related services ("Products”) from BioPorto Diagnostics A/S ("BIOPORTO") and Buyer. Any deviating conditions or reservations by Buyer shall only be binding if confirmed in writing by BIOPORTO. Conditions are also applicable in individual cases where Terms are not attached, but which Buyer has been made aware of the Terms.